Skip to main content
Free trial

Ask AI to review this stock

Copy the prompt to get recent events, historical reactions, and a short research brief.

Tell your AI:

Help me set up FinLab and analyze ABBV AbbVie Inc.. Please read: https://finlab.finance/en/setup?stock=ABBV

No install, open FinLab Studio

ABBV

AbbVie Inc. Healthcare As of 2026-07-31 Updated daily after market close

strong quality, premium valuation.

1 active signal
52-week adjusted-price high
This page refreshes daily after the close. Add AbbVie Inc. to your watchlist to track signal changes on your next visit.
Valuation 25Quality 81Growth 56Momentum 76Risk / liquidity 86

Is AbbVie Inc. a buy? Fundamentals and valuation first

  • Quality is top-tier. Operating margin ranks above roughly 82% of the liquid US common-stock universe. TTM ROE is about 13.2%.

  • Valuation is expensive. TTM P/E is in the 96th percentile, above most peers.

  • Recent volatility is comparatively low. 60-day annualized volatility is in the 27th percentile. Average 20-day dollar volume is about $1,428.5M.

  • Signals are active now. 52-week adjusted-price high currently holds; the tables below show what followed in this stock’s own history.

Historical evidence

Signals active now

Each active condition is tested against this stock’s own history and benchmarked versus the S&P 500.

52-week adjusted-price high

Active

Adjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.

19 historical occurrences (since 2017-06-05)
Average forward return after 52-week adjusted-price high。20-day: Win 55.6%, Sample 18, Median +1.31%, Excess +1.11%, Beat mkt rate 50%；60-day: Win 58.8%, Sample 17, Median +3.37%, Excess +1.6%, Beat mkt rate 41.2%；120-day: Win 82.4%, Sample 17, Median +5.64%, Excess +4.66%, Beat mkt rate 52.9%

120 days after: historical avg +12.13%

20-day +1.73%
60-day +4.22%
120-day +12.13%
20-day
60-day
120-day
Win
55.6%
58.8%
82.4%
Sample
18
17
17
Median
+1.31%
+3.37%
+5.64%
Excess
+1.11%
+1.6%
+4.66%
Beat mkt rate
50%
41.2%
52.9%

Over 17 occurrences, 120-day forward avg gained 12.13%, beat the market by 4.66 pts; win rate 82.4%.

Valuation regime and forward returns

Daily TTM P/E is converted into an expanding own-history percentile, then grouped into five valuation regimes. Forward returns use adjusted prices over the next 240 trading days.

PE percentile bandSample days240-day avg returnMedianWin rateAvg excess (vs index)
0-20 108+26% +24.3% 100% -12.7%
20-40 233+5.9% +4.1% 61.4% -10.8%
40-60 140+11.4% +12.5% 85% -7.6%
60-80 188+21% +26.3% 87.8% +14.4%
80-100 You are here711+19.8% +18.3% 98.6% +7.3%

Quarterly EPS is aligned by SEC filing date before it is forward-filled to daily prices. The expanding percentile uses only information available up to each day.

Current TTM P/E is about 123.05, placing it in the 96.1 own-history percentile, inside the 80-100 bucket.

Valuation × momentum analogs

Each historical day is grouped by own-history P/E tercile and 60-day momentum direction, then tested for the next 120-trading-day adjusted return.

Valuation
Momentum
Cheap (own-history bottom third)
Middle
Expensive (own-history top third)
60-day momentum up
+6.4%
Win rate 85.9% Excess -8.3%
85d
-0.7%
Win rate 46.5% Excess -5.9%
217d
Now
+6.8%
Win rate 72.8% Excess +0.3%
603d
60-day momentum down
+11.2%
Win rate 88.8% Excess -1.5%
143d
+6.6%
Win rate 67.8% Excess -2%
90d
+15.8%
Win rate 94.2% Excess +8.8%
362d

Currently in “Expensive (own-history top third) × 60-day momentum up”: across 603 historical days, 120-day forward avg gained 6.8%, win rate 72.8%, beat the market by 0.3%.

Days = trading days in this bucket; returns use adjusted prices, ex-costs. 60-day momentum: direction of this stock's price over the past 60 trading days.

Market-wide momentum baseline

Across 97,878 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.26%, a 58.3% positive-return rate, and +2.90 percentage points of average excess return versus the S&P 500.

Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).

Signals not active now

Inactive signals still show the stock-specific historical forward-return distribution for context.

Top-quintile 6-month momentum

Pending

The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.

7 times historically; 60-day forward avg +2.86%, win rate 57.1%, beating the market by +1.39 pts on average.

Filed revenue acceleration

Pending

TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.

8 times historically; 60-day forward avg -4.1%, win rate 37.5%, beating the market by -6.98 pts on average.

EPS surprise beat

Pending

Reported EPS beat consensus estimate by at least 5%; event date is the earnings-surprise timestamp.

7 times historically; 60-day forward avg +3.42%, win rate 80%, beating the market by -0.45 pts on average.

Method and limits

  • Returns use us_price:adj_close, adjusted for splits and dividends where available.
  • Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
  • Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
  • The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
  • Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
  • Overlapping event windows are descriptive distributions, not independent samples.

This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.